Causes
The primary cause of GSM is the decline in estrogen levels, which leads to thinning, drying, and inflammation of the tissues in the genitourinary tract. While primarily associated with menopause, other conditions can also cause estrogen deficiency.- Menopause: The natural cessation of menstrual periods, leading to a significant drop in ovarian estrogen production.
- Surgical Menopause: Bilateral oophorectomy (removal of both ovaries).
- Medical Treatments:
- Chemotherapy: Can induce temporary or permanent ovarian failure.
- Radiation Therapy: Especially pelvic radiation, can damage ovarian function.
- Anti-estrogen Drugs: Such as aromatase inhibitors used in breast cancer treatment (e.g., anastrozole, letrozole, exemestane) or tamoxifen.
- GnRH Agonists: Used to treat endometriosis or fibroids (e.g., leuprolide) by suppressing ovarian function.
- Lactation: Breastfeeding can cause a temporary estrogen deficiency.
- Certain Autoimmune Conditions: Can sometimes affect ovarian function.
- Disorders of the Pituitary Gland: Affecting hormone production.
Symptoms
Symptoms of GSM can vary in severity and may affect one or more areas of the genitourinary tract. They tend to worsen over time if left untreated.- Vaginal Symptoms:
- Vaginal Dryness: The most common symptom, leading to discomfort.
- Vaginal Burning: A persistent sensation.
- Vaginal Itching: Can range from mild to severe.
- Dyspareunia: Pain or discomfort during sexual activity due to dryness and thinning of tissues.
- Decreased Vaginal Lubrication: During sexual arousal.
- Vaginal Bleeding: Especially after intercourse due to fragile tissues.
- Shortening and Narrowing of the Vagina: Over time, if untreated.
- Urinary Symptoms:
- Urinary Urgency: A sudden, strong need to urinate.
- Dysuria: Pain or burning during urination.
- Recurrent Urinary Tract Infections (UTIs): Due to changes in the urethra and bladder lining.
- Nocturia: Waking up at night to urinate.
- Stress Urinary Incontinence: Leaking urine with coughing, sneezing, or laughing.
- Vulvar Symptoms:
- Vulvar Dryness, Itching, or Burning.
- Changes in Vulvar Appearance: Loss of labial fullness, thinning of pubic hair.
Diagnosis
Diagnosis of GSM is primarily clinical, based on a woman's symptoms and a physical examination. There are no specific lab tests required for diagnosis, though some may be done to rule out other conditions.- Medical History: The healthcare provider will ask about symptoms, menstrual history, menopausal status, sexual activity, and any relevant medical conditions or medications.
- Physical Examination:
- Pelvic Exam: The provider will visually inspect the vulva and vagina for signs of atrophy, such as pallor, loss of rugae (vaginal folds), thinning, redness, and dryness.
- Assessment of Vaginal pH: Atrophic vaginal tissue often has a higher (more alkaline) pH.
- Evaluation of Vaginal Maturation Index (VMI): A microscopic examination of vaginal cells to assess the proportion of superficial, intermediate, and parabasal cells, reflecting estrogen status.
- Urine Test: To rule out a urinary tract infection if urinary symptoms are present.
- Other Tests (less common): Occasionally, blood tests for hormone levels might be considered, but they are not typically necessary for GSM diagnosis.
Treatment
Treatment for GSM aims to alleviate symptoms and improve the health of the genitourinary tissues. Treatment options range from non-hormonal lubricants to hormonal therapies.- Non-Hormonal Treatments (First-line for mild symptoms):
- Vaginal Moisturizers: Regular use (2-3 times per week) to hydrate vaginal tissues and maintain moisture. Examples include Replens, Hydralin, or over-the-counter options.
- Vaginal Lubricants: Used at the time of sexual activity to reduce friction and discomfort. Water-based or silicone-based lubricants are generally recommended.
- Regular Sexual Activity: Can help maintain vaginal elasticity and blood flow.
- Local Estrogen Therapy (Low-dose vaginal estrogen):
- Considered the most effective treatment for moderate to severe GSM symptoms. Directly targets the vaginal and vulvar tissues with minimal systemic absorption.
- Vaginal Cream: Applied with an applicator (e.g., Estrace, Premarin).
- Vaginal Tablet/Pessary: Inserted into the vagina (e.g., Vagifem, Imvexxy).
- Vaginal Ring: A flexible ring inserted into the vagina that releases estrogen consistently for three months (e.g., Estring).
- Systemic Estrogen Therapy:
- Oral pills, patches, gels, or sprays. Primarily used to manage other menopausal symptoms like hot flashes, but can also improve GSM symptoms. Typically prescribed when other systemic menopausal symptoms are also bothersome.
- Selective Estrogen Receptor Modulators (SERMs):
- Ospemifene (Osphena): An oral SERM that acts like estrogen on vaginal tissue, improving dryness and dyspareunia.
- Prasterone (Intrarosa): A vaginal insert containing DHEA (dehydroepiandrosterone), which is converted to estrogens and androgens within the vaginal cells.
- Laser Therapy: Emerging treatments like CO2 laser therapy are being explored, though long-term efficacy and safety are still under investigation.
Making GSM Treatment Work
Genitourinary syndrome of menopause is among the most treatable conditions and the least treated, because symptoms are rarely volunteered and treatment is stopped as soon as it works.
How vaginal estrogen is actually used
A low-dose vaginal cream, tablet, insert, or ring is used nightly for about two weeks and then twice a week indefinitely. Dryness improves within a few weeks, but pain with intercourse and urinary symptoms can take two to three months, and stopping brings the symptoms back within months because the underlying estrogen deficiency has not changed. The doses in local products are a small fraction of those in systemic hormone therapy, blood levels stay in the postmenopausal range, and no progestogen is needed to protect the uterus. Our hormone therapy risks and benefits article covers where systemic treatment fits.
The warning label and who can use it
The boxed warning on every estrogen product reflects systemic doses in older trials, not low-dose vaginal treatment. Vaginal estrogen is generally considered acceptable for women with a history of breast cancer whose symptoms have not responded to nonhormonal measures, decided together with the oncologist, with more caution during aromatase inhibitor treatment. Ospemifene and vaginal prasterone are alternatives when estrogen itself is declined.
The urinary side
Thinning of the urethra and bladder lining is why recurrent urinary tract infections cluster after menopause, and vaginal estrogen reduces recurrences substantially, which our recurrent UTI prevention article covers. Urgency and frequency often improve too, though overactive bladder that persists is treated on its own, and leakage with coughing responds to pelvic floor therapy, as our pelvic floor first article explains.
What GSM is confused with
Itching and burning that do not improve with estrogen may be lichen sclerosus, which needs a steroid ointment and is described in our lichen sclerosus after 50 article, or a yeast or bacterial infection, covered in our BV versus yeast guide. Any bleeding after menopause is evaluated even when thin tissue is the likely cause. Scented soaps, wipes, panty liners, and tight synthetic clothing in the local heat all worsen irritation.
Moisturizers, lubricants, and the long view
A vaginal moisturizer used two or three times a week is different from a lubricant used during sex, and mild symptoms often need only the first. Both can continue alongside estrogen. Symptoms progress without treatment as the years after menopause accumulate, so the question is how to keep treating comfortably. Our genito-urinary team manages ongoing care. The American College of Obstetricians and Gynecologists and MedlinePlus publish patient guidance on treatment.
If dryness, pain, or repeated urinary infections have followed menopause, schedule a visit; treatment is simpler than most people expect.